These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26654406)

  • 1. Drug Pricing: Has the Camel's Back Finally Been Broken?
    Lipman AG
    J Pain Palliat Care Pharmacother; 2015; 29(4):332-3. PubMed ID: 26654406
    [No Abstract]   [Full Text] [Related]  

  • 2. [Reference prices].
    Rey Abella ME
    Aten Primaria; 1999 Sep; 24(5):252-4. PubMed ID: 10590555
    [No Abstract]   [Full Text] [Related]  

  • 3. [Parallel import of drugs for better and for worse].
    Krabbe U
    Ugeskr Laeger; 2004 Feb; 166(7):611. PubMed ID: 15005051
    [No Abstract]   [Full Text] [Related]  

  • 4. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
    [No Abstract]   [Full Text] [Related]  

  • 5. Manufacturers urge German government to revise proposals for pricing new drugs.
    Stafford N
    BMJ; 2012 Jun; 344():e4069. PubMed ID: 22695911
    [No Abstract]   [Full Text] [Related]  

  • 6. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
    Sturm AC
    Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
    [No Abstract]   [Full Text] [Related]  

  • 8. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WHO must defend patients' interests, not industry.
    Cawthorne P; Ford N; Limpananont J; Tienudom N; Purahong W
    Lancet; 2007 Mar; 369(9566):974-5. PubMed ID: 17382809
    [No Abstract]   [Full Text] [Related]  

  • 10. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 11. Protect pharmaceutical innovation.
    Musselwhite LW; Andrews J
    Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
    [No Abstract]   [Full Text] [Related]  

  • 12. [The new reference prices: an opportunity for efficient management of medication].
    Ausejo Segura M
    Aten Primaria; 2005 Feb; 35(2):64-6. PubMed ID: 15727746
    [No Abstract]   [Full Text] [Related]  

  • 13. Australian drugs scheme threatens free-trade talks.
    Fickling D
    Lancet; 2004 Jan; 363(9405):299. PubMed ID: 14753208
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceuticals and medical devices: cost savings.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug Pricing Regulation Pushed From Many Sides.
    Kirkner RM
    Manag Care; 2016 Jan; 25(1):14-5. PubMed ID: 26882623
    [No Abstract]   [Full Text] [Related]  

  • 17. Expansion of bulk-buy drug programme in China.
    Rahimi S
    Lancet Oncol; 2019 Oct; 20(10):e564. PubMed ID: 31523020
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug Regulation and Pricing--Can Regulators Influence Affordability?
    Eichler HG; Hurts H; Broich K; Rasi G
    N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
    [No Abstract]   [Full Text] [Related]  

  • 19. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug manufacturer on the savings package of Ulla Schmidt. "Grip in the moth box of planned economics"].
    Schmidt K
    MMW Fortschr Med; 2001 Nov; 143(44):52. PubMed ID: 11732398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.